Thomas Lettner

Thomas Lettner

Auto-generated profile, based on publicly available information

Thomas Lettner

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2009 in FEMS Yeast Research
Verified
Journal Article
Open access
PDF file
UZUte Zeidler
Ute Zeidler
TLThomas Lettner
Thomas Lettner
CLCaroline Lassnig
Caroline Lassnig
MMMathias Mã¼Ller
Mathias Mã¼Ller
RLRobert Lajko
Robert Lajko
ABArnold Bito
Arnold Bito
True hyphal growth of Candida albicans can be induced by several environmental conditions and contributes significantly to the high virulence of this

1 November 2017 in Molecular Therapy
Verified
Journal Article
Open access
TKThomas Kocher
Thomas Kocher
PPPatricia Peking
Patricia Peking
AKAlfred Klausegger
Alfred Klausegger
EMEva Murauer
Eva Murauer
JHJosefina Piñón Hofbauer
Josefina Piñón Hofbauer
UKUlrich Koller
Ulrich Koller
With the ability to induce rapid and efficient repair of disease-causing mutations, CRISPR/Cas9 technology is ideally suited for gene therapy approaches for recessively and dominantly inherited monogenic disorders. In this study, we have corrected a causal hotspot mutation in exon 6 of the keratin 14 gene (KRT14) that results in generalized severe epidermolysis bullosa simplex (EBS-gen sev), using a double-nicking strategy targeting intron 7, followed by homology-directed repair (HDR). Co-delivery into EBS keratinocytes of a Cas9 D10A nickase (Cas9n), a predicted single guide RNA pair specific for intron 7, and a minicircle donor vector harboring the homology donor template resulted in a recombination efficiency of >30% and correction of the mutant KRT14 allele. Phenotypic correction of EBS-gen sev keratinocytes was demonstrated by immunofluorescence analysis, revealing the absence of disease-associated K14 aggregates within the cytoplasm. We achieved a promising safety profile for the CRISPR/Cas9 double-nicking approach, with no detectable off-target activity for a set of predicted off-target genes as confirmed by next generation sequencing. In conclusion, we demonstrate a highly efficient and specific gene-editing approach for KRT14, offering a causal treatment option for EBS.

1 May 2018 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
VWVerena Wally
Verena Wally
AHAlain Hovnanian
Alain Hovnanian
JLJuliette Ly
Juliette Ly
HBHana Buckova
Hana Buckova
VBVictoria Brunner
Victoria Brunner
JBJohann W. Bauer
Johann W. Bauer
Epidermolysis bullosa simplex (EBS) is a rare genetic, blistering skin disease for which there is no cure. Treatments that address the pathophysiology of EBS are needed. Compare the impact of 1% diacerein cream with placebo in reducing the number of blisters in EBS. In a randomized, placebo-controlled, phase 2/3 trial we used a 1% diacerein topical formulation to treat defined skin areas in 17 patients. In a 2-period crossover trial, patients were randomized to either placebo or diacerein for a 4-week treatment and a 3-month follow-up in period 1. After a washout, patients were crossed over during period 2. The prespecified primary end point was the proportion of patients with a reduction of number of blisters by more than 40% from baseline in selected areas over the treatment episode. Of the patients receiving diacerein, 86% in episode 1 and 37.5% in episode 2 met the primary end point (vs 14% and 17% with placebo, respectively). This effect was still significant after the follow-up. Changes in absolute blister numbers were significant for the diacerein group only. No adverse effects were observed. Low patient numbers and no invasive data acquisition because of clinical burden in children. This trial provides evidence of the impact of 1% diacerein cream in the treatment of EBS.

22 September 2010 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
VWVerena Wally
Verena Wally
MBMarietta Brunner
Marietta Brunner
TLThomas Lettner
Thomas Lettner
MWMartin Wagner
Martin Wagner
UKUlrich Koller
Ulrich Koller
JBJohann W. Bauer
Johann W. Bauer
The major challenge to a successful gene therapy of autosomal dominant genetic diseases is a highly efficient and specific knock-down or repair of the disease-causing allele. In epidermolysis bullosa simplex-type Dowling–Meara (EBS-DM), a single amino acid exchange in exon 1 of the keratin 14 gene (K14) triggers a severe skin phenotype, characterized by blistering of the skin and mucous membranes after minor trauma. We chose spliceosome-mediated RNA trans-splicing to specifically replace exons 1–7 of the K14 gene. In this approach, the mutated coding region is replaced by an RNA-trans-splicing molecule (RTM) that incorporates a binding domain (BD) and the wild-type sequence of K14. Since the BD is crucial for the trans-splicing functionality, we developed a fluorescence-based RTM screen consisting of an RTM library containing random BDs. Co-transfection of the library with a target molecule enabled us to identify highly functional RTMs. The best RTMs were adapted for endogenous trans-splicing in an EBS-DM patient cell line. In this cell line, we were able to detect functional, efficient and correct trans-splicing on RNA and protein levels. Scratch assays confirmed phenotypic reversion in vitro. Owing to concomitant knock-down and repair of the mutated allele, we assume that trans-splicing is a promising tool for the treatment of autosomal dominant genetic disease.

1 July 2013 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
VWVerena Wally
Verena Wally
TLThomas Lettner
Thomas Lettner
PPPatricia Peking
Patricia Peking
DPDoris Peckl-Schmid
Doris Peckl-Schmid
EMEva Murauer
Eva Murauer
JBJohann W. Bauer
Johann W. Bauer

1 August 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
OMOliver P. March
Oliver P. March
TLThomas Lettner
Thomas Lettner
AKAlfred Klausegger
Alfred Klausegger
MAMichael Ablinger
Michael Ablinger
TKThomas Kocher
Thomas Kocher
JRJulia Reichelt
Julia Reichelt
Epidermolytic ichthyosis is a skin fragility disorder caused by dominant-negative mutations in KRT1 or KRT10. No definitive restorative therapies exist that target these genetic faults. Gene editing can be used to efficiently introduce frameshift mutations to inactivate mutant genes. This can be applied to counter the effect of dominantly inherited diseases such as epidermolytic ichthyosis. In this study, we used transcription activator-like effector nuclease technology, to disrupt disease-causing mutant KRT10 alleles in an ex vivo cellular approach, with the intent of developing a therapy for patients with epidermolytic ichthyosis. A transcription activator-like effector nuclease was designed to specifically target a region of KRT10, upstream of a premature termination codon known to induce a genetic knockout. This proved highly efficient at gene disruption in a patient-derived keratinocyte cell line. In addition, analysis for off-target effects indicated no promiscuous gene editing-mediated disruption. Reversion of the keratin intermediate filament fragility phenotype associated with epidermolytic ichthyosis was observed by the immunofluorescence analysis of correctly gene-edited single-cell clones. This was in concurrence with immunofluorescence and ultrastructure analysis of murine xenograft models. The efficiency of this approach was subsequently confirmed in primary patient keratinocytes. Our data demonstrate the feasibility of an ex vivo gene-editing therapy for more than 95.6% of dominant KRT10 mutations.